Core Insights - The series of meetings organized by the National Healthcare Security Administration (NHSA) reflects a strong commitment from the decision-making level to support the development of innovative drugs and medical devices, providing clearer and more stable policy expectations for the industry [2][4]. Group 1: Policy Support for Innovative Drugs - The NHSA has held five meetings focusing on various aspects of supporting innovative drugs, including comprehensive value assessment, new technology development, real-world research, and investment strategies [2][4]. - The NHSA emphasizes a multi-departmental approach to optimize collaboration and support for the innovative drug ecosystem [1][2]. Group 2: Key Directions for Support - The NHSA outlined five key directions for supporting innovative drugs: providing policy guidance for R&D, supporting true innovation based on clinical outcomes, encouraging differentiated innovation, comprehensive evaluation of clinical and economic value, and enhancing communication between policy departments and the industry [5][6]. - The NHSA also highlighted the importance of collaboration between basic medical insurance and commercial insurance to create a multi-tiered support system for innovation [5]. Group 3: Data Utilization in Drug Development - The NHSA plans to leverage healthcare data to support innovative drug development by reducing investment costs, enhancing investment prospects, and mitigating risks [6][7]. - Experts at the meetings expressed the need for improved data utilization to transition drug development from experience-based to data-driven approaches, which could significantly reduce time and resource costs [7]. Group 4: Encouraging Long-term Investment - The NHSA reported that since its establishment in 2018, the cumulative expenditure of the healthcare fund has reached 18.04 trillion yuan, with an annual growth rate of 11%, supporting both demand and supply in the healthcare sector [8]. - There is a call for encouraging long-term patient capital to invest in early-stage R&D and key technologies rather than short-term speculative investments [8][9]. Group 5: Innovations in Pricing and Market Access - The NHSA introduced new pricing policies to facilitate the entry of innovative drugs into the market, including a mechanism for the first price of newly listed drugs and optimizing service access [9][10]. - Medical institutions and pharmaceutical companies shared insights on the clinical application of new technologies and the development of innovative drugs during the meetings [10].